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ABSTRACT
Sarcopenia and frailty are recognized as key risk factors for adverse outcomes in patients on renal replacement therapy or
with non-dialysis chronic kidney disease (CKD). However, there is still debate about their pathogenesis and, thus, about the
best therapeutic approaches, as well as the impact on outcomes of current approaches based on different exercise
programmes. In the past two issues of Clinical Kidney Journal, several manuscripts address the issue of sarcopenia in CKD
from the point of view of pathogenesis and new therapeutic approaches, monitoring of results, implementation of exercise
programmes and specific potential benefits of exercise programmes in dialysis and non-dialysis CKD patients, as assessed
by clinical trials.
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The frailty syndrome has been defined as the presence of three
or more of the following criteria: unintentional weight loss, self-
reported exhaustion, weakness, slow walking speed and low
physical activity [1]. Frailty is associated with high mortality [1].
The prevalence of frailty is much higher in dialysis-dependent
chronic kidney disease (CKD) patients than in the older adult
population (60 versus 11% in one study) [2]. Even among non-
dialysis CKD patients, a whopping 81% reported excessive tired-
ness [3]. There are several frailty scores associated to markers of
inflammation, hospitalization and protein-energy wasting [4, 5].
Sarcopenia is a clinical correlate of frailty, which is common in
CKD and is associated with lower quality of life and physical
functioning, as well as with an increased risk of major adverse
cardiovascular events and mortality. Sarcopenia may be associ-
ated with bone disease (osteosarcopenia). In recent issues of
Clinical Kidney Journal (ckj), several manuscripts address the issue
of sarcopenia in CKD from the point of view of pathogenesis [6],
monitoring and its clinical significance [7, 8], implementation
and impact of exercise programmes [7, 9] and specific potential
benefits of exercise programmes in dialysis and non-dialysis
CKD patients, as assessed by clinical trials [10, 11].
A better understanding of the pathogenesis of sarcopenia
and, specifically, of CKD-associated sarcopenia may facilitate
the development of novel therapeutic approaches. Recent
advances have focused on skeletal muscle renewal, the role of
mitochondrial pathophysiology and exercise mimetics. Skeletal
muscle progenitor cells are termed satellite cells and provide
new nuclei to myofibres, thus contributing to increase and
maintain muscle mass. O’Sullivan et al. [6] review the impact of
CKD on satellite cells and the contribution of these cells to the
altered myogenic response to exercise.
An acquired mitochondrial myopathy has being described in
CKD [12]. Multiple abnormalities of mitochondrial structure,
function and composition are present in experimental and clini-
cal CKD. Skeletal muscle biopsies from patients with advanced
CKD show lower mitochondrial volume density and
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mitochondrial DNA copy number than controls. In mice, CKD
induces autophagy and mitochondria dysfunction in skeletal
muscle. Muscle overloading to mimick resistance exercise in-
creased mitochondrial copy number, and reversed the CKD-
induced decrease in the master regulator of mitochondrial
biogenesis peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PGC-1a) [13]. Both skeletal muscle and kid-
ney PGC-1a are downregulated by inflammatory mediators such
as TNF-like weak inducer of apoptosis (TWEAK), contributing to
sarcopenia and kidney injury, respectively [14, 15]. Interestingly,
outside the CKD context, the beneficial effect of exercise on
PGC-1a may be mediated by modulation of TWEAK [16]. In this
regard, CKD is a pro-inflammatory state and anti-inflammatory
strategies may be explored to reverse sarcopenia [17].
Based on an improved understanding of pathogenesis, one
therapeutic approach being explored for sarcopenia is the use of
exercise mimetics, drug treatments that may result in similar
molecular adaptations to those elicited by exercise [18]. Recent
reports have addressed whether microRNA, such as the miR-
23a/miR-27a cluster, may be used as exercise mimetics for mus-
cle wasting in CKD [18]. The beneficial effect was associated
with improvements in proteolysis, muscle regeneration and
inflammatory cytokines. However, miR-23a also maintains mi-
tochondrial integrity, although dosing considerations may be
important, as it also suppresses PGC-1a [19, 20].
Gollie et al. [7] review the available tools to monitor skeletal
muscle composition and function in the CKD context.
Specifically, they review the strengths and limitations of dual-
energy X-ray absorptiometry and bioelectrical impedance to es-
timate body composition and of proxy measures of skeletal
muscle quality using ultrasound. Another approach is the
analysis of self-reported measures. Clarke et al. [8] report that
the self-reported measures of physical performance Duke
Activity Status Index (physical function) and General Practice
Physical Activity Questionnaire (habitual activity regarding
walking behaviour) were independently associated with sur-
vival in non-dialysis CKD [8]. These measures could be added to
the use of imaging or more conventional studies [21].
Finally, several recent ckj manuscripts address therapy for
sarcopenia and frailty, and randomized clinical trials (RCTs)
addressing this issue. A 2015 systematic review on the effects of
exercise in CKD patients concluded that most RCTs included
small samples, were of short duration and applied aerobic exer-
cises. The strongest evidence was for the effects of aerobic exer-
cise on improving physical fitness, muscular strength and
quality of life in dialysis patients, but the evidence base was
missing for non-dialysis CKD [22]. A more recent 2018 system-
atic review and meta-analysis disclosed favourable effects of
aerobic exercise on estimated glomerular filtration rate (eGFR)
and exercise tolerance, following an on average 35-week aerobic
training programme when compared with standard care in CKD
G3–4 [23]. Despite this, Gollie et al. [7] review evidence that pro-
gressive resistance exercise improves skeletal muscle mass and
strength and health-related quality of life and report that most
evidence still derives from end-stage renal disease studies and
limited evidence is available in earlier stages of CKD [7].
One of the issues of exercise programmes is implementa-
tion. Staff knowledge, patient motivation and equipment prob-
lems had been identified as barriers to exercise on dialysis. An
increase in the uptake of exercise on dialysis from 23% to 74%
was achieved by an intervention focused on patient and nursing
staff education, equipment modification and patient motivation
schemes [24]. More recently, Young et al. [9] identified patient
and staff barriers to intradialytic exercise implementation
through a quality improvement project focused on interven-
tions designed to increase patient and staff engagement based
on the Theoretical Domains Framework, using a series of ‘Plan,
Do, Study, Act’ cycles. Patient participation dropped to 48% and
adherence to 63% by 12 months. Only patients that completed
the programme benefited from it, displaying significant
improvements in functional ability and a reduction in depres-
sion [9].
Only RCTs will provide the required level of evidence to in-
fluence clinical practice. Aragoncillo et al. [10] describe the
PHYSICALFAV RCT (NCT03213756) that will evaluate the useful-
ness of preoperative isometric exercise for 8 weeks in
pre-dialysis or dialysis patients on a main endpoint of rate of
primary failure of a new arteriovenous fistula. This study
addresses a key point in need of clarification as identified by re-
cent vascular access guidelines [25]. Wilkinson et al. [11] report
that 12 weeks (3 times/week) of supervised aerobic exercise
alone or in combination with resistance training in non-dialysis
CKD patients resulted in a reduction in the total number of
health-related quality of life symptoms reported by 17%.
Aerobic exercise reduced the frequency of ‘shortness of breath’,
and the intrusiveness of ‘sleep disturbance’, ‘loss of muscular
strength/power’, ‘muscle spasm/stiffness’ and ‘restless legs’.
The addition of resistance exercise further decreased ‘loss of
muscular strength/power’. No changes were seen in subjective
physical function or physical activity levels.
This information adds to recent RCTs in dialysis or non-
dialysis patients. In patients with Stage 3 CKD, randomization
to 16 weeks of supervised moderate-intensity aerobic exercise
three times per week led to a mild improvement in VO2 peak,
but did not induce changes in high density lipoprotein (HDL)
particle size or favourable lipid profile modifications [26]. In an-
other RCT in non-dialysis CKD patients, the addition of resis-
tance exercise to aerobic exercise conferred greater increases in
muscle mass and strength than aerobic exercise alone [27]. In
111 patients with moderate-to-severe CKD, the combination of
4-month dietary calorie restriction and aerobic exercise had sig-
nificant, albeit clinically modest, benefits on body weight, fat
FIGURE 1: A roadmap to improve sarcopenia and CKD: from bench to bedside.
Drawn based on information from Refs [6–11]. DXA, dual-energy X-ray
absorptiometry.
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mass and markers of oxidative stress and inflammatory response
[28]. A 14-week intradialytic training programme induced signifi-
cant improvements on physical performance. However, the rate
of clinically meaningful responders was low and the level of re-
sponsiveness depended on baseline physical status, highlighting
the need to individualize exercise prescription [29].
In summary, there is increasing interest in actively address-
ing sarcopenia and frailty. However, clinical success will depend
on identifying novel avenues of therapy through a better under-
standing of pathogenic pathways, optimizing the tools to moni-
tor the impact of therapy, individuating the therapeutic
approaches, including the optimal dose and combination of dif-
ferent exercise modalities, and addressing barriers to imple-
mentation in both healthcare staff and patients (Figure 1).
ACKNOWLEDGEMENTS
The authors were supported by FIS PI16/02057, PI18/01366,
ISCIII-RETIC REDinREN RD016/0009 Fondos FEDER, Sociedad
Espa~nola de Nefrologı´a, Comunidad de Madrid B2017/BMD-
3686 CIFRA2-CM and Miguel Servet MS14/00133 to M.D.S.-N.
CONFLICT OF INTEREST STATEMENT
None declared.
REFERENCES
1. Fried LP, Tangen CM, Walston J et al. Frailty in older adults:
evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56:
M146–M156
2. Nixon AC, Bampouras TM, Pendleton N et al. Frailty and
chronic kidney disease: current evidence and continuing
uncertainties. Clin Kidney J 2018; 11: 236–245
3. Brown SA, Tyrer FC, Clarke AL et al. Symptom burden in
patients with chronic kidney disease not requiring renal re-
placement therapy. Clin Kidney J 2017; 10: 788–796
4. Johansen KL, Dalrymple LS, Delgado C et al. Factors associ-
ated with frailty and its trajectory among patients on hemo-
dialysis. Clin J Am Soc Nephrol 2017; 12: 1100–1108
5. Gracia-Iguacel C, Gonza´lez-Parra E, Barril-Cuadrado G et al.
Defining protein-energy wasting syndrome in chronic kid-
ney disease: prevalence and clinical implications. Nefrologia
2014; 34: 507–519
6. O’Sullivan TF, Smith AC, Watson EL. Satellite cell function,
intramuscular inflammation and exercise in chronic kidney
disease. Clin Kidney J 2018; 11: 810–821
7. Gollie JM, Harris-Love MO, Patel SS et al. Chronic kidney dis-
ease: considerations for monitoring skeletal muscle health
and prescribing resistance exercise. Clin Kidney J 2018; 11:
822–831
8. Clarke AL, Zaccardi F, Gould DW et al. Association of self-
reported physical function with survival in patients with
chronic kidney disease. Clin Kidney J 2019; 12: 122–128
9. Young HML, Jeurkar S, Churchward DR et al. Implementing a
theory-based intradialytic exercise programme in practice: a
quality improvement project. Clin Kidney J 2018; 11: 832–840
10. Aragoncillo I, Ligero JM, Hevia C et al. Rationale and design of
the PHYSICALFAV trial: a randomized controlled trial to
evaluate the effect of preoperative isometric exercise on vas-
cular calibre and maturation of autologous arteriovenous
fistulas. Clin Kidney J 2018; 11: 841–845
11. Wilkinson TJ, Watson EL, Gould DW et al. Twelve weeks of
supervised exercise improves self-reported symptom bur-
den and fatigue in chronic kidney disease: a secondary
analysis of the “ExTra CKD” trial. Clin Kidney J 2019; 12:
113–121
12. Rao M, Jaber BL, Balakrishnan VS. Chronic kidney disease
and acquired mitochondrial myopathy. Curr Opin Nephrol
Hypertens 2018; 27: 113–120
13. Su Z, Klein JD, Du J et al. Chronic kidney disease induces
autophagy leading to dysfunction of mitochondria in skele-
tal muscle. Am J Physiol Renal Physiol 2017; 312: F1128–F1140
14. Hindi SM, Mishra V, Bhatnagar S et al. Regulatory circuitry of
TWEAK-Fn14 system and PGC-1a in skeletal muscle atrophy
program. FASEB J 2014; 28: 1398–1411
15. Ruiz-Andres O, Suarez-Alvarez B, Sa´nchez-Ramos C et al.
The inflammatory cytokine TWEAK decreases PGC-1a ex-
pression and mitochondrial function in acute kidney injury.
Kidney Int 2016; 89: 399–410
16. Padr~ao AI, Figueira ACC, Faustino-Rocha AI et al. Long-term
exercise training prevents mammary tumorigenesis-
induced muscle wasting in rats through the regulation of
TWEAK signalling. Acta Physiol (Oxf) 2017; 219: 803–813
17. Castillo-Rodrı´guez E, Pizarro-Sa´nchez S, Sanz AB et al. Inflam-
matory cytokines as uremic toxins: Ni Son Todos Los Que
Estan, Ni Estan Todos Los Que Son. Toxins (Basel) 2017; 9: 114
18. Mak RH, Cheung WW. MicroRNA as novel exercise mimetic
for muscle wasting in CKD. J Am Soc Nephrol 2017; 28:
2557–2559
19. Zhang B, Liu SQ, Li C et al. MicroRNA-23a curbs necrosis dur-
ing early T cell activation by enforcing intracellular reactive
oxygen species equilibrium. Immunity 2016; 44: 568–581
20. Russell AP, Wada S, Vergani L et al. Disruption of skeletal
muscle mitochondrial network genes and miRNAs in amyo-
trophic lateral sclerosis. Neurobiol Dis 2013; 49: 107–117
21. Sergi G, Trevisan C, Veronese N et al. Imaging of sarcopenia.
Eur J Radiol 2016; 85: 1519–1524
22. Barcellos FC, Santos IS, Umpierre D et al. Effects of exercise
in the whole spectrum of chronic kidney disease: a system-
atic review. Clin Kidney J 2015; 8: 753–765
23. Vanden Wyngaert K, Van Craenenbroeck AH, Van Biesen W
et al. The effects of aerobic exercise on eGFR, blood pressure
and VO2 peak in patients with chronic kidney disease stages
3-4: A systematic review and meta-analysis. PLoS One 2018;
13: e0203662
24. Abdulnassir L, Egas-Kitchener S, Whibley D et al. Captivating
a captive audience: a quality improvement project increas-
ing participation in intradialytic exercise across five renal di-
alysis units. Clin Kidney J 2017; 10: 516–523
25. Ibeas J, Roca-Tey R, Vallespı´n J et al. Spanish Clinical
Guidelines on vascular access for haemodialysis. Nefrologia
2017; 37 (Suppl 1): 1–191
26. Miele EM, Headley SAE, Germain M et al. High-density lipo-
protein particle pattern and overall lipid responses to a
short-term moderate-intensity aerobic exercise training in-
tervention in patients with chronic kidney disease. Clin
Kidney J 2017; 10: 524–531
27. Watson EL, Gould DW, Wilkinson TJ et al. Twelve-week com-
bined resistance and aerobic training confers greater bene-
fits than aerobic training alone in nondialysis CKD. Am J
Physiol Renal Physiol 2018; 314: F1188–F1196
28. Ikizler TA, Robinson-Cohen C, Ellis C et al. Metabolic effects
of diet and exercise in patients with moderate to severe
CKD: a randomized clinical trial. J Am Soc Nephrol 2018; 29:
250–259
29. Valenzuela PL, de Alba A, Pedrero-Chamizo R et al.
Intradialytic exercise: one size doesn’t fit all. Front Physiol
2018; 9: 844
112 | A. Ortiz and M.D. Sanchez-Ni~no
D
ow
nloaded from
 https://academ
ic.oup.com
/ckj/article-abstract/12/1/110/5308488 by guest on 22 M
ay 2020
